tiprankstipranks

Viva Biotech Reports Improved Profitability Amid Revenue Decline

Story Highlights
Viva Biotech Reports Improved Profitability Amid Revenue Decline

Viva Biotech Holdings ( (HK:1873) ) has provided an update.

Viva Biotech Holdings announced its annual results for the year ended December 31, 2024, reporting a decrease in revenue by 7.8% to RMB 1,986.7 million and a decrease in gross profit by 6.9% to RMB 687.4 million. Despite these declines, the company achieved a net profit of RMB 222.0 million, a significant improvement from the previous year’s loss. The adjusted Non-IFRS net profit also increased, highlighting the company’s efforts to improve operational efficiency and financial performance. The announcement also included a change in the composition of the nomination committee, reflecting a strategic move to strengthen governance.

More about Viva Biotech Holdings

Viva Biotech Holdings is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on providing drug discovery and development services, catering to the needs of pharmaceutical and biotech companies.

YTD Price Performance: 125.58%

Average Trading Volume: 7,356,227

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.16B

Learn more about 1873 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App